뉴스

Malviya Nagar hotel owner claims no direct mgmt

Malviya Nagar fire: LOC issued against hotel owner

Malviya Nagar fire: Residents help diners flee

Delhi Malviya Nagar restaurant fire: Over 20 dead, several rescued from basement

Srinagar Airport runway to shutdown from Oct 1 to 16

Centre withdraws draft sugarcane order

New Delhi: The Centre has withdrawn the draft Sugarcane (Control) Order, 2026, saying it needs to be revisited in the light of objections received from state governments and other stakeholders.The Food Ministry had circulated the draft for public comments, with a May 20 deadline.Also Read: Sugarcane FRP hiked to Rs 365/quintal for 2026-27 season"Based on the suggestions/comments received from state governments and other stakeholders, it is considered necessary to revisit the draft Sugarcane (Control) Order, 2026," the ministry said in an office memorandum.The draft sought to replace the 60-year-old Sugarcane (Control) Order, 1966, with a new regulatory framework that proposed, among other things, bringing the ethanol and khandsari sectors under government regulation.The move drew opposition from khandsari units and farmers. The draft had proposed redefining a khandsari unit as one with more than 10 workers and a crushing capacity of over 500 tonnes per day. Under the existing rules, a khandsari unit is defined as one with 20 or more workers, with no capacity limit.Also Read: Gujarat govt's 'revolutionary' decision to provide Rs 1,500 cr financial relief to sugar cooperativesSources said the proposed definition would have brought a large number of small-scale, labour-intensive units under the regulatory ambit, adversely affecting farmers who generally receive better prices from khandsari units than from sugar mills.BJP MP Sanjeev Balyan, who represents Muzaffarnagar in Uttar Pradesh, said on social media the government had decided to withdraw the order "in the interest of farmers"."This demonstrates that under the leadership of Prime Minister Narendra Modi, the government formulates every policy by placing the consent of the farmers and their welfare above all," he said.

US drug regulator flags lapses at Dabur plant

The U.S. Food and Drug Administration has flagged data integrity, manufacturing and maintenance lapses at one of Dabur India's plants following an inspection earlier this year, according to an inspection report. Dabur is one of India's oldest and largest consumer goods companies, describing itself as one of the world's largest suppliers of Ayurvedic products with a legacy of ‌over 140 ⁠years. It ⁠sells a range of over-the-counter and consumer health products in the United States, including cough and cold rubs, antifungal creams, pain relief gels and oral care products. The findings, issued after the FDA inspected the company's factory in the country's western region of Dadra and Nagar Haveli in January, said some units in the facility posed risks of microbiological contamination. The report also said critical manufacturing records were falsified ⁠to conceal ‌that equipment meant to make certain products had been used for multiple other products. A live bird and bird droppings were found in ⁠the raw material warehouse, about 30 feet from packaging materials. An apparent unidentified black substance was also seen covering more than 25% of ceiling surfaces in both the raw material warehouse and the finished drug product storage warehouse, according to the report, which was made public earlier this week. The findings come amid heightened regulatory scrutiny of Indian drugmakers over quality controls for medicines and health products exported to the United States, their ‌largest overseas market. The FDA inspector also questioned the reliability of testing at the plant, noting that although microbiology test results were reported as within limits, significant contamination was observed ⁠in multiple samples during the inspection. Dabur did not immediately respond to a Reuters request for comment. Following a form 483, which is issued after a U.S. FDA inspection, companies usually respond to the regulator with corrective steps taken to address the concerns. The report also said management had not reviewed drug production and quality records to determine compliance with regulatory requirements before batches were released to the market, and cited deficiencies in equipment cleaning and maintenance procedures.